Aurinia Pharma Shares Down 2.35% Following Earlier Rating Change By Canaccord's Neil Maruoka; Maruoka Tells Benzinga Change Was Due To Speculative Nature Of Investment;  Says 'It was technically listed as a downgrade; although I don't view it this way'